A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi^™, ENF) plus binimetinib (Mektovi^®, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activating mutation. Patient...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Mohamed M. Hefnawy, Mohammed M. Alanazi, Abdullah M. Al-Hossaini, Abdulaziz I. Alnasser, Adel S. El-Azab, Yousef A. Bin Jardan, Mohamed W. Attwa, Manal A. El-Gendy
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2022-12-01
Cyfres:	Molecules
Pynciau:	LC–MS/MS melanoma encorafenib binimetinib rat plasma pharmacokinetics
Mynediad Ar-lein:	https://www.mdpi.com/1420-3049/28/1/79
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!